Synaffix BV

Formed in 2010, Synaffix is a Netherlands-based biotechnology company exclusively focused on continued advancement of a best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, the vision of Synaffix is to become the preferred partner in the development of these complex biological therapeutics and realize its ambition - connect to cure.

http://www.synaffix.com/

Team Members
more about
Bauke Anninga
Principal
more about
Hakan Goker
Managing Director
Latest News Entry
2023/01/05
Synaffix Enters $2 Billion License Agreement with Amgen
  • Total potential deal value up to $2 billion plus tiered royalties on commercial sales
  • Synaffix to provide Amgen access to its proprietary antibody-drug conjugate (ADC) technologies
2023/01/04
Hummingbird Bioscience and Synaffix Enter $150m License Agreement

Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies
Synaffix to receive up to $150m in upfront and milestone payments plus royalties

2022/12/13
Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company has been awarded ‘Business Development Team of Year’ at the annual Scrip Awards ceremony held on the 30th of November, at the Royal Lancaster in London, UK. This award follows shortly after securing ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony last month in London and ‘Best ADC Platform Technology’ at the World ADC Conference 2022 in September.

2022/11/16
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old Billingsgate in London, UK.

2022/10/18
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology
CliCr® further expands the repertoire of payloads suitable for conjugation by enhancing reactivity, stability and hydrophilicity

2021/09/29
Third ADC with Synaffix’s Technology Enters Clinical Development

Partner Shanghai Miracogen (fully owned by LEPU BIOPHARMA CO., LTD) commences US Phase I/II trial with ADC designed to treat solid tumors

MRG004A selected for clinical development based on highly competitive efficacy and tolerability in preclinical studies compared to conventional ADC technology

Over 10 ADCs currently being developed by Synaffix licensees

2020/07/23
Synaffix Announces Third Deal Expansion by ADC Therapeutics

Synaffix B.V. announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies

2019/01/16
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors

2018/05/14
Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen

Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert,
the former Chief Scientific Officer of ImmunoGen, Inc.

2017/12/06
Synaffix Launches toxSYN™, a New Platform of ADC Payloads

AMSTERDAM, NETHERLANDS – December 6, 2017 – Synaffix BV, a biotechnology company that has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the launch of a new platform of highly potent cytotoxic ADC payloads that will be integrated into its existing ADC platform. With this expansion, Synaffix becomes a one-stop provider for technologies required to rapidly translate antibodies into proprietary ADC products.

2017/11/29
Synaffix Commands IP Space of Glycan-Conjugated ADCs Through Major Expansion of Granted Patent Portfolio

Synaffix BV, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the granting of a key patent that encompasses the entire GlycoConnect™ process.

2017/10/11
ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement

Synaffix BV announced today that ADC
Therapeutics has triggered a second target-specific license under their Commercial License
Agreement dated October 2016, to develop an antibody-drug conjugate (ADC) using Synaffix’s
proprietary site-specific antibody-drug conjugation technology. As part of the original
agreement, ADC Therapeutics retains an option to take a limited number of additional singletarget
licenses for their potential future programs.

2017/09/24
Synaffix Awarded "Runner Up" Postion for Best Platform ADc Technology

World ADC is pleased to announce the finalists in the 4th Annual World ADC Awards. The World ADC Awards showcase the innovation, leadership and devotion shown by the best companies, teams and individuals in the industry. Across 9 categories the Awards will recognise the extraordinary endeavours, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.

2017/05/16
Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States

exclusively focused on the development of industry-leading antibody-drug conjugate
(ADC) technology platforms, today announced that a key patent covering its HydraSpace™
spacer technology has been granted by the United States Patent and Trademark Office
(US 9,636,421 B2).

2017/02/20
New Data Demonstrate Significant Expansion of Therapeutic Index vs Cysteine-Engineered ADCs

AMSTERDAM, NETHERLANDS – February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.

2016/12/08
Key Synaffix Patent Covering Glycan-Conjugated ADC Process Granted in the United States

AMSTERDAM, NETHERLANDS – December 8, 2016 – Synaffix BV, a biotechnology
company exclusively focused on the development of industry-leading antibody-drug
conjugate (ADC) technology platforms, today announced that a key patent that
encompasses the entire GlycoConnect™ process used to prepare glycan-conjugated ADCs
has been granted in the US (US 9,504,758 B2), further strengthening its IP portfolio.

2016/10/20
Synaffix Enters into a Commercial License Agreement with ADC Therapeutics

AMSTERDAM, NETHERLANDS – October 20, 2016 – Synaffix BV announced today it has entered
into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™
and HydraSpace™ site-specific antibody-drug conjugate technologies.
Under the terms of the agreement, ADC Therapeutics has been granted a single-target license
for one of its preclinical programs and has also been granted an option to take a limited number
of additional single-target licenses for potential future programs.

2016/07/20
Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and Expands Its Scientific Advisory Board

AMSTERDAM, THE NETHERLANDS — Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics. The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect™ and HydraSpace™, generate ADCs with significantly improved therapeutic index when compared directly to Kadcyla® and Adcetris®, the two FDA-approved ADCs for the treatment of Her2-positive breast cancer and multiple lymphoma indications, respectively.

all related news
all portfolio news